GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Biotechnology

More

  • Promising cancer drugs Friday, 17 Apr 2015 | 4:42 PM ET
    Promising cancer drugs

    The fight against Alzheimer's disease and cancer take center stage at conferences this weekend. Details, with CNBC's Meg Tirrell.

  • This is what's driving biotech Wednesday, 8 Apr 2015 | 5:30 AM ET
    This is what's driving biotech

    Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.

  • Halftime's hottest trades today: BTU, FB, JPM & XBI Tuesday, 7 Apr 2015 | 2:00 PM ET
    Halftime's hottest trades today: BTU, FB, JPM & XBI

    Halftime's hottest trades today: 6 trades in 50 seconds. Exploring social media rallies, biotech's reversal, earnings season, Peabody Energy, and JP Morgan.

  • LONDON, April 1- A European project to streamline drug approvals moves up a gear next week when regulators sit down with the first company to have an experimental product assessed under a new flexible pilot scheme. In the United States, the Food and Drug Administration has introduced a successful "breakthrough" designation, which has speeded up approval of...

  • The next buzz in biotech Tuesday, 31 Mar 2015 | 11:30 AM ET
    The next buzz in biotech

    As gene therapy emerges in the biotech industry and Phil Nadeau, Cowen and Company Biotechnology Analyst, explains why it could be the next billion dollar industry.

  • Genfit sinks 31%, but CEO defends liver drug results Friday, 27 Mar 2015 | 3:30 PM ET
    A researcher works in a laboratory of French biopharmaceutical company Genfit, in Loos, northern France, Nov. 15, 2012.

    The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.

  • Will the biotech run resume? Friday, 27 Mar 2015 | 12:00 AM ET
    Will the biotech run resume?

    After a tough week for biotech stocks, David Seaburg of Cowen & Co. and Craig Johnson of Piper Jaffray call the next move.

  • Déjà vu for biotechs Thursday, 26 Mar 2015 | 2:33 PM ET
    Déjà vu for biotechs

    CNBC's Meg Tirrell reports on the recent drop in biotechs and whether it is a threat to the overall market.

  • Be selective in biotech: Pro Wednesday, 25 Mar 2015 | 3:20 PM ET
    Be selective in biotech: Pro

    CNBC contributor Barbara Ryan of Clermont Partners, discusses whether biotech is a good place to be right now, and how investors

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • TEL AVIV/ FRANKFURT, March 12- Two years after scientists cooked up the first test tube beef hamburger, researchers in Israel are working on an even trickier recipe: the world's first lab-grown chicken. Professor Amit Gefen, a bioengineer at Tel Aviv University, has begun a year-long feasibility study into manufacturing chicken in a lab, funded by a non-profit...

  • Biotech brawl: Bull vs. ...bull Friday, 27 Feb 2015 | 3:16 PM ET
    Biotech brawl: Bull vs. ...bull

    Eric Schmidt, Cowen & Co. biotech analyst, thinks biotech will continue to be a great business and will move higher. Insight, with Geoff Porges, Sanford Bernstein.

  • Who can beat the 'superbug'? Thursday, 19 Feb 2015 | 5:27 PM ET
    Who can beat the 'superbug'?

    A new antibiotic-resistant "superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. What companies may be on track to combat the deadly virus, with CNBC's Meg Tirrell.

  • It turns out Genghis Khan made a whole lot of us Friday, 30 Jan 2015 | 3:00 PM ET
    Statue of Genghis Khan

    New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.

  • US earnings: 'Tech to the rescue' Thursday, 29 Jan 2015 | 5:00 AM ET
    US earnings: 'Tech to the rescue'

    Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.

  • The rise and rise of biotech stocks? Friday, 16 Jan 2015 | 5:20 AM ET
    The rise and rise of biotech stocks?

    Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.

  • Biopharma's challenges in 2015 Wednesday, 14 Jan 2015 | 9:30 AM ET
    Biopharma's challenges in 2015

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • I am a better person: Sam Waksal Tuesday, 13 Jan 2015 | 8:36 AM ET
    I am a better person: Sam Waksal

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • I'm not running the show: Sam Waksal Tuesday, 13 Jan 2015 | 8:33 AM ET
    I'm not running the show: Sam Waksal

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.

  • Sam Waksal's IPO biotech plans Tuesday, 13 Jan 2015 | 8:31 AM ET
    Sam Waksal's IPO biotech plans

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.